FDA posts Class II recall of Apothecary Pharma tirzepatide, NAD+ vials
The North Carolina compounder had received an FDA letter in December 2025 citing insanitary conditions in sterile drug preparation.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 23 11:47 ETSource: KRQE
The wire
- 01The FDA designated a Class II recall covering 22 vials of tirzepatide injection 18mg/mL and one vial of NAD+ injection 200mg/mL from Apothecary Pharma LLC of Cary, North Carolina, over lack of sterility assurance.
- 02Compounders continue supplying GLP-1s though tirzepatide and semaglutide came off the shortage list in late 2024 and early 2025; prescribers and patients should check lot numbers and NDCs.
- 03No illnesses have been linked to the recall and the FDA has not issued consumer instructions; patients are told to stop use and contact their clinician.
From the source
Read at krqe.comNationwide recall on these compound GLP-1 drugs
( NewsNation ) — The FDA has issued a recall for 23 GLP-1 compounded vials from Apothecary Pharma LLC due to lack of assurance that the vials are sterile.
